论文部分内容阅读
ＨＢｓＡｇ兼ＨＢｅＡｇ、抗－ＨＢｃ均阳性母亲所生婴儿的感染率高达８５％，作者将在该院出生的本组婴儿１４２例分为３组，运用不同来源的基因工程疫苗接种。Ｉ组：用痘苗重组ＤＮＡ乙肝疫苗５７例，在婴儿娩出后１个月、６月龄进行注射，每次２０ｕｇ。ＩＩ组：应用乙型肝炎疫苗（基因工程细胞生产）４１例，其用法同Ｉ组。ＩＩＩ组：疫苗来源同Ｉ组，出生时同时给以乙肝免疫球蛋白（ＨＢＩＧ）１支，含量为２００Ｕ／ｍｌ，每次ｌｍｌ，臂部肌内注射，１、６月龄重复注射上述疫苗１０ｕｇ。其保护率分别为８８．２％、８５．９％、１００％，抗－ＨＢｓ阳转率分别为８２％、８６％、９８％、经过统计学处理，ＩＩＩ组与Ｉ组相比，Ｐ＜０．０５，差异有显著性；ＩＩ组与ＩＩＩ组相比，Ｐ＜０．０５，差异亦有显著性。ＩＩＩ组免疫方案优于Ｉ、ＩＩ组，且在ＩＩＩ组４４例中，无１例感染，其免疫效果亦优于血源性乙肝疫苗。基因疫苗的问世，为乙肝母婴传播阻断开辟了新的途径。
The infection rate of babies born to HBsAg-positive, HBeAg-positive and anti-HBc-positive mothers was as high as 85%. The authors divided 142 infants of this group who were born in this hospital into 3 groups and vaccinated them with genetically engineered vaccines from different sources. Group I: vaccinia recombinant DNA hepatitis B vaccine in 57 cases, 1 month after infancy, 6 months old for injection, each 20ug. Group II: Hepatitis B vaccine (genetically engineered cells) 41 cases, the same usage with the I group. Group III: The vaccine source with the same group I, at the same time give birth to a hepatitis B immunoglobulin (HBIG) 1, the content of 200U / ml, each lml, intramuscular arm, 1, 6 months of repeated injection of the vaccine 10ug . The protection rates were 88.2%, 85.9% and 100%, respectively. The anti-HBs positive rates were 82%, 86% and 98%, respectively. After statistical analysis, 0.05, the difference was significant; Group II compared with Group III, P <0.05, the difference was also significant. Group III immunization program was superior to group I and II, and in group III 44 cases, no case of infection, the immune effect is also superior to the blood-borne hepatitis B vaccine. The advent of gene vaccines has opened up new avenues for the blockage of mother-to-child transmission of hepatitis B.